End-Stage Heart Failure Trial Completes Enrollment
Filed with ASX · · 3 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Corporate Updates at Healthcare Conferences
- Retail Entitlement Offer
- Underwritten A$50.7M Raise Closes Institutional Allocation
- Fully Underwritten A$50.7 Million Entitlement Offer
- Potential For Accelerated Market Entry In Advanced CHF
Later from Mesoblast
- RA Phase 2 Trial Results Presented At ACR Annual Meeting
- Mesoblast Provides Corporate Update and Q1 Financial Results
- Response to ASX Aware Letter Query
- MSB Named Global Technology Leader In Cell Therapy Industry
- Mesoblast Grants TiGenix License For Treatment of Fistulae
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast